DOCSLIB.ORG

Emtree Terms Changed in January 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Emtree Terms Changed in January 2017 Emtree Terms Added and Changed (January 2017) This is an overview of new terms added and changes made in the first Emtree release in 2017. Overall, Emtree has grown by 782 preferred terms (269 drug terms and 513 non-drug terms) compared with the previous version released in September 2016. In total Emtree now counts 75,488 preferred terms. Because the terms added include replacements for existing preferred terms (which become synonyms of the new terms) as well as completely new concepts, the number of terms added exceeds the net growth in Emtree. Other changes could include the merging of two or more existing preferred terms into a single concept. The terms added and changed are summarized below and specified in detail on the following pages. Emtree Terms Added in January 2017 930 new terms (including 148 replacement terms and promoted synonyms) have been added to Emtree as preferred terms in version January 2017 (compared to September 2016): 308 drug terms (terms assigned to the Chemicals and Drugs facet). 622 non-drug terms (terms not assigned as Chemicals and Drugs). The new terms (including the replacement terms and the promoted synonyms) are listed as Terms Added on the following pages. Note that many of these terms will have been indexed prior to 2017 (typically as candidate terms), sometimes for several years, before they were added to Emtree. Emtree Terms Changed in January 2017 148 terms (39 drug terms and 109 non-drug terms) from Emtree September 2016 have been replaced by 148 different terms in January 2017 (39 drug terms and 109 non-drug terms). Of these, 129 terms (34 drug terms and 95 non-drug terms) are new (e.g. new generic names for drug chemical names) and have been assigned creation date 2017; the remaining 19 replacement terms (5 drug terms and 14 non-drug terms) were already present in Emtree. No drug terms were replaced by a non-drug term, no non-drug terms were replaced by a drug term. No preferred terms were deleted. Changes are presented in alphabetical order of the new terms. Emtree Terms Added in January 2017 2 Drug terms 1,7 bis(3,4 dimethoxyphenyl) 4 cyclobutylmethyl atuveciclib 1,6 heptadiene 3,5 dione audencel 2 acetylamino 2 deoxy mannopyranose autophagy related protein 3 (5 amino 2 methyl 4 oxoquinazolin 3(4h) autophagy related protein 12 yl)piperidine 2,6 dione autophagy related protein 5 3 [4 (1h imidazol 1 ylmethyl)phenyl] 5 (2 autophagy related protein 7 methylpropyl)thiophene 2 [(n autophagy related protein 8 family butyloxylcarbamate) sulphonamide] sodium baclofen plus naltrexone plus sorbitol 6' methyl 5 ortho (5 amino 5,6 dideoxy alpha baliforsen talofuranosyl) paromamine sulfate baltaleucel T abbv 8e12 bivalirudin ABC transporter subfamily G bmn 270 acetylsalicylic acid plus omeprazole bps 804 acp 501 bpx 501 adalimumab atto branaplam ADAM12 protein bridged bicyclo compounds ADAMTS protein brilanestrant ADAMTS7 protein butyrophilin ADAMTS9 protein cab1803 adeno associated virus vector cadherin related protein aerase calcium release activated calcium channel 2 afm13 caly 002 agerafenib camrelizumab agil as canine adenovirus plus canine distemper virus plus alicapistat canine parainfluenza virus plus canine alidornase alfa parvovirus vaccine alkB protein casimersen alkylated DNA repair protein alkB homolog 1 cavosonstat alkylated DNA repair protein alkB homolog 4 cenegermin alkylated DNA repair protein alkB homolog 5 cergutuzumab alkylated DNA repair protein alkB homolog 8 chitinase 3 like protein 1 aln as1 chlorquinaldol plus promestriene alpha ketoglutarate dependent dioxygenase alkB cholesterol 24 hydroxylase homolog 2 citarinostat alpha ketoglutarate dependent dioxygenase alkB cosfroviximab homolog 3 coversin alpha ketoglutarate dependent dioxygenase FTO crs 207 alxn 1540 cupabimod alxn1007 cyclophilin C alxn1210 cytochrome P450 family 1 anakinra cytochrome P450 family 11 ancient DNA cytochrome P450 family 12 andecaliximab cytochrome P450 family 17 antibody drug conjugate cytochrome P450 family 19 antigen peptide transporter 2 cytochrome P450 family 2 apararenone cytochrome P450 family 21 apimostinel cytochrome P450 family 24 apolipoprotein B mRNA editing enzyme catalytic cytochrome P450 family 26 polypeptide like cytochrome P450 family 27 aprutumab cytochrome P450 family 3 aprutumab ixadotin cytochrome P450 family 4 asciminib cytochrome P450 family 46 at982 cytochrome P450 family 6 atesidorsen cytochrome P450 family 7 atir101 cytochrome P450 family 8 ATP dependent DNA ligase darolutamide Emtree Terms Added in January 2017 3 dezamizumab lanabecestat dezapelisib landipirdine diroximel fumarate larcaviximab discoidin domain receptor larotrectinib discoidin domain receptor 1 lentiglobin bb305 discoidin domain receptor 2 lesinidase alfa dtx301 letolizumab eccs 50 lidocaine plus phenylephrine plus tropicamide edetic acid plus sodium nitrite lidocaine plus prilocaine elacestrant lipid droplet associated protein elapegademase lisavanbulin elezanumab lumicitabine elivaldogene tavalentivec lupartumab emapalumab lupartumab amadotin ensartinib lutikizumab enzaplatovir lysine acetyltransferase epertinib lysophospholipid receptor affecting agent eptinezumab lysophospholipid receptor agonist Equisetum arvense extract lysophospholipid receptor antagonist eretidigene velentivec mannose 6 phosphate receptor binding protein 1 erythromycin plus isotretinoin mardepodect etanercept szzs mastic etrasimod mating factor evobrutinib mating hormone A factor fatty acid binding protein 7 methyl accepting chemotaxis protein fezolinetant midomafetamine fluorouracil plus salicylic acid miridesap flurdihydroergotamine mivebresib forkhead box protein M1 MutL protein homolog 1 fosmetpantotenate n carboxymethylglycylthreonylhistidyl 3,3 fremanezumab diphenylalanylpiperidincarboxy 3 furosemide plus spironolactone ylarginylmethylthiocystylarginyltryptophylamino fused ring compound hexanyl n carboxamidomethylglycine n germanium 68 plus gallium 68 hexadecylamide glucagon receptor agonist N Myc proto oncogene protein golodirsen nacubactam gs030 naltrexone plus oxycodone gsk 3377794 navoximod hemochromatosis protein nebivolol plus valsartan hemoglobin betafumaril neflamapimod heparesc nelatimotide hepastem NIMA interacting peptidylprolyl isomerase hepatitis A virus cellular receptor 2 NIMA related kinase homeobox protein Nkx-2.5 NIMA related kinase 1 homer scaffolding protein Nogo receptor house dist mite allergen extract Nogo receptor 1 ifabotuzumab Nogo receptor 2 ilmetropium iodide obicetrapib imlatoclax ogd 201 infliximab dyyb oleclumab inositol polyphosphate 5 phosphatase omidenepag isopropyl interferon induced helicase C domain containing padsevonil protein 1 palucorcel interleukin 1 receptor like 1 protein paracetamol plus thiocolchicoside inxn 3002 Parkinson disease associated protein ionis httrx pegapamodutide ionis ttrrx pegunigalsidase alfa isis sod1rx pegvorhyaluronidase alfa istiratumab Emtree Terms Added in January 2017 4 peptidyl prolyl cis trans isomerase NIMA Shc signaling adaptor protein interacting 1 SHC transforming protein 1 peptidylprolyl cis trans isomerase NIMA SHC transforming protein 2 interacting 4 SHC transforming protein 3 perilipin 1 shp655 perilipin 4 signaling lymphocytic activation molecule perilipin 5 sinecatechins phenylalanylserylarginyltyrosylalanylarginine small leucine rich proteoglycan acetate solute carrier protein phloroglucinol plus trimethylphloroglucinol somatrogon phosphatidylinositol 3,4,5 trisphosphate 5 splicing factor U2AF phosphatase squill extract phosphoinositide phosphatase stromal interaction molecule pimodivir suvratoxumab polygonum extract SWI/SNF related matrix associated actin dependent porgaviximab regulator of chromatin subfamily B member 1 poseltinib T guard (antibody) primula flower extract tavolixizumab prolylprolylthreonylvalylprolylthreonylarginine telisotuzumab proprotein convertase 9 telisotuzumab vedotin protein deglycase DJ-1 tenofovir exalidex protein Jagged 1 Thymus vulgaris extract protein Jagged 2 tirabrutinib protein phosphatase 2c tonabacase provitamin tonogenconcel PTB associated splicing factor tozuleristide pyrin transcription activator like effector qr 010 trastuzumab duocarmazine qr 110 trefoil factor rabbit haemorrhagic disease vaccine trefoil factor 1 ravoxertinib trefoil factor 2 recombinant parathyroid hormone[1-84] trefoil factor 3 regulatory factor X transcription factor tripartite motif protein regulatory factor X1 tumor necrosis factor alpha induced protein 3 reltecimod tumor protein p73 remtolumab tumor suppressor p53 binding protein 1 ribaxamase Twist related protein 1 RNA splicing factor Twist related protein 2 rogaratinib valnivudine rosiptor vandefitemcel rosmantuzumab velagliflozin rozanolixizumab veldoreotide sa237 vinorelbine tartrate satoreotide vorolanib seladelpar vunakizumab seltorexant Werner syndrome ATP dependent helicase sequestosome 1 xoma 358 serabelisib zalmoxis (drug) serine threonine protein kinase ULK1 zona pellucida glycoprotein serrate jagged protein Emtree Terms Added in January 2017 5 Non-drug terms 1 hour pad test benign male genital tract tumor A-375 cell line benign neoplasm A-549 cell line benign nervous system tumor abdominal wound closure benign respiratory tract tumor abnormal value benign urinary tract tumor Abrus precatorius benign urogenital tract tumor abuse deterrant formulation betel leaf activity tracker betel quid acute febrile encephalopathy Bifidobacterium longum subsp. infantis acute HIV infection Bifidobacterium longum subsp. longum acute myeloid leukemia Bifidobacterium pseudocatenulatum
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Mcfeely Washington 0250E 19
    © Copyright 2019 Savannah Jane Kerr McFeely Clinical Significance and Regulatory Framework for the Evaluation of Organic Anion Transporting Polypeptide 1B-Based Drug-Drug Interactions Savannah Jane Kerr McFeely A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2019 Reading Committee: Isabelle Ragueneau-Majlessi, Chair Jashvant Unadkat Bhagwat Prasad Program Authorized to Offer Degree: Pharmaceutics University of Washington Abstract Clinical Significance and Regulatory Framework for the Evaluation of Organic Anion Transporting Polypeptide 1B-Based Drug-Drug Interactions Savannah Jane Kerr McFeely Chair of the Supervisory Committee: Dr. Isabelle Ragueneau-Majlessi Department of Pharmaceutics This dissertation research aims to conduct a comprehensive analysis of the clinical role of organic anion transporting polypeptides (OATPs) 1B1 and 1B3 and the regulatory approach for their evaluation. The work included here has identified the most relevant clinical substrates and inhibitors. Additionally, the contributing factors in the variability of in vitro inhibition constants as well as real-world implications for OATP1B1/1B3 drug-drug interactions are discussed. In Chapter 2, six compounds were identified as potential clinical markers of OATP1B1/1B3 activity through the use of a novel indexing system. These drugs were identified from a list of 34 clinical substrates identified from a thorough analysis of the available in vitro and in vivo data. These findings also suggest that the risk for comedication interactions involve drugs from multiple therapeutic areas showing a reliance on hepatic uptake via the OATP transporters. Chapters 3 seeks to better understand the variability of in vitro inhibition data. By analyzing available OATP1B1/1B3 IC50 values, the primary contributing factors to in vitro variability were identified as the cell system used and inclusion of a preincubation with the inhibitor.
    [Show full text]
  • Download PDF Document
    Journal for ImmunoTherapy of Cancer 2019, 7(Suppl 1):283 https://doi.org/10.1186/s40425-019-0764-0 MEETINGABSTRACTS Open Access 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2 National Harbor, MD, USA. 10 November 2019 Published: 6 November 2019 About this supplement These abstracts have been published as part of Journal for ImmunoTherapy of Cancer Volume 7 Supplement 1, 2019. The full contents of the supplement are available online at https://jitc.biomedcentral.com/articles/supplements/volume-7-supplement-1. Please note that this is part 2 of 2. Poster Presentations median survival; 3) FTN203 did not negate the efficacy of anti- PD-1 or anti-PD-L1 immunotherapy antibody when combined; 4) Biomarkers, Immune Monitoring, and Novel FTN203 significantly improved the efficacy of anti-PD-1 by further Technologies reducing the tumor growth (by 80% on day 26, P=0.046) and in- creasing the median survival (by 5 days or 14%, Log-rank test P= P501 0.031), against the combo of COMPLETE and anti-PD-1; 5) None Dietary deprivation of non-essential amino acids improves anti-PD- of the mono or combo treatments caused body weight loss. 1 immunotherapy in murine colon cancer Conclusions Zehui Li, PhD, Grace Yang, PhD, Shuang Zhou, PhD, Xin Wang, MD, PhD, Our data supports the use of dietary NEAA deprivation to improve Xiyan Li, PhD the efficacy of anti-PD-1 or anti-PD-L1 immunotherapy for colorectal Filtricine, Inc., Santa Clara, CA, United States cancer without noticeable side effects.
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Anti- Tumor Activity in Multiple ER+ Breast Cancer Patient-Derived Xenograft Models
    Author Manuscript Published OnlineFirst on May 4, 2017; DOI: 10.1158/1078-0432.CCR-16-2561 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ORIGINAL RESEARCH Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti- tumor activity in multiple ER+ breast cancer patient-derived xenograft models Teeru Bihani1, Hitisha K. Patel1, Heike Arlt1, Nianjun Tao1, Hai Jiang1, Jeffrey L. Brown1, Dinesh M. Purandare1, Gary Hattersley1, and Fiona Garner1* 1Radius Health, Inc, Waltham, MA, USA Running Title: Elacestrant inhibits growth of ER+ breast cancer PDX models Key words: elacestrant, SERD, ESR1 mutations, CDK4/6, breast cancer, hormone signaling and inhibitors, preclinical studies of endocrine-related cancers, steroid hormones and receptors, xenograft models, novel antitumor agents. ABBREVIATIONS 17β-estradiol – E2 aromatase inhibitor – AI AUC – area under the curve estrogen receptor-alpha gene – ESR1 estrogen receptor – ER gene regulated by estrogen in breast cancer 1 – GREB1 human epidermal growth factor 2 - Her2 immunohistochemical, immunohistochemistry - IHC patient-derived xenograft – PDX progesterone receptor – PGR, PR 1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 4, 2017; DOI: 10.1158/1078-0432.CCR-16-2561 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. quantitative reverse transcriptase polymerase chain reaction – RT-qPCR selective estrogen receptor degrader – SERD selective estrogen receptor modulator – SERM trefoil factor 1 – TFF1 percent tumor growth inhibition - %TGI Competing Interest and Financial Disclosures: All authors are employees of Radius Health, Inc. *Corresponding Author: Fiona Garner; Radius Health, 950 Winter Street, Waltham, MA, Phone: 617-551-4000, Fax: 617-551-4701, [email protected] 2 Downloaded from clincancerres.aacrjournals.org on September 27, 2021.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • A Phase 1B Study Evaluating the Effect of Elacestrant Treatment on Estrogen
    University of Groningen A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging Jager, Agnes; de Vries, Elisabeth G E; der Houven van Oordt, C Willemien Menke-van; Neven, Patrick; Venema, Clasina M; Glaudemans, Andor W J M; Wang, Yamei; Bagley, Rebecca G; Conlan, Maureen G; Aftimos, Philippe Published in: Breast cancer research DOI: 10.1186/s13058-020-01333-3 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Jager, A., de Vries, E. G. E., der Houven van Oordt, C. W. M., Neven, P., Venema, C. M., Glaudemans, A. W. J. M., Wang, Y., Bagley, R. G., Conlan, M. G., & Aftimos, P. (2020). A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. Breast cancer research, 22(1), [97]. https://doi.org/10.1186/s13058-020-01333-3 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
    [Show full text]
  • BREAST CANCER METASTATIC DORMANCY and EMERGENCE, a ROLE for ADJUVANT STATIN THERAPY by Colin Henry Beckwitt Bachelor of Science
    BREAST CANCER METASTATIC DORMANCY AND EMERGENCE, A ROLE FOR ADJUVANT STATIN THERAPY by Colin Henry Beckwitt Bachelor of Science in Biological Engineering, Massachusetts Institute of Technology, 2013 Submitted to the Graduate Faculty of The School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2018 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Colin Henry Beckwitt It was defended on May 22, 2018 and approved by Chairperson: Donna Beer Stolz, PhD, Associate Professor, Department of Cell Biology Zoltán N. Oltvai, MD, Associate Professor, Department of Pathology Partha Roy, PhD, Associate Professor, Departments of Bioengineering and Pathology Kari N. Nejak-Bowen, MBA, PhD, Assistant Professor, Department of Pathology Linda G. Griffith, PhD, School of Engineering Teaching Innovation Professor, Departments of Biological and Mechanical Engineering Dissertation Advisor: Alan Wells, MD, DMSc, Thomas J. Gill III Professor, Department of Pathology ii Copyright © by Colin Henry Beckwitt 2018 iii BREAST CANCER METASTATIC DORMANCY AND EMERGENCE, A ROLE FOR ADJUVANT STATIN THERAPY Colin Henry Beckwitt University of Pittsburgh, 2018 Breast cancer is responsible for the most new cancer cases and is the second highest cause of cancer related deaths among women. Localized breast cancer is effectively treated surgically. In contrast, metastatic cancers often remain undetected as dormant micrometastases for years to decades after primary surgery. Emergence of micrometastases to form clinically evident metastases complicates therapeutic intervention, making survival rates poor. The often long lag time between primary tumor diagnosis and emergence of metastatic disease motivates the development or repurposing of agents to act as safe, long term adjuvants to prevent disease progression.
    [Show full text]
  • Targeting Protein Quality Control Pathways in Breast Cancer Sara Sannino and Jeffrey L
    Sannino and Brodsky BMC Biology (2017) 15:109 DOI 10.1186/s12915-017-0449-4 REVIEW Open Access Targeting protein quality control pathways in breast cancer Sara Sannino and Jeffrey L. Brodsky* cancers. Finally, triple negative breast cancers (TNBC) Abstract are ER-, PR-, and HER2-negative [2, 3]. The efficient production, folding, and secretion of ER-positive breast cancer groups are especially preva- proteins is critical for cancer cell survival. However, lent and mainly afflict postmenopausal women because cancer cells thrive under stress conditions that luminal cells become more sensitive to estrogen (17β-es- damage proteins, so many cancer cells overexpress tradiol or E2) levels as a result of hormonal fluctuations molecular chaperones that facilitate protein folding [4]. Activation of the ER signaling cascade stimulates cell and target misfolded proteins for degradation via division, tumor growth, and metastasis. Therefore, ER- the ubiquitin-proteasome or autophagy pathway. positive patients are initially treated with anti-estrogen Stress response pathway induction is also important therapies [5] (Table 1). Tamoxifen was one of the first for cancer cell survival. Indeed, validated targets for FDA approved drugs used to treat these patients, is a anti-cancer treatments include molecular chaperones, non-steroid inhibitor of the receptor, and blocks down- components of the unfolded protein response, the stream signaling [6, 7]. However, in many tamoxifen ubiquitin-proteasome system, and autophagy. We treated patients, ER activation was still detected, will focus on links between breast cancer and highlighting the demand for improved compounds and these processes, as well as the development of new targets [8]. In fact, since tamoxifen was approved, drug resistance, relapse, and treatment.
    [Show full text]
  • Appendix 1 – Protocol for Preventing Or Reversing Chronic Disease The
    Appendix 1 – Protocol for Preventing or Reversing Chronic Disease The first author has developed a protocol over the past decade for preventing or reversing chronic disease based on the following systemic medical principle: “at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective”[1]. The protocol methodology refines the age-old principles of both reducing harm in addition to providing treatment, and allows better identification of factors that contribute to the disease process (so that they may be eliminated if possible). These contributing factors are expansive and may include a combination of Lifestyle choices (diet, exercise, smoking), iatrogenic and biotoxin exposures, environmental/occupational exposures, and psychosocial stressors. This strategy exploits the existing literature to identify patterns of biologic response using biomarkers from various modalities of diagnostic testing to capture a much broader list of potential contributing factors. Existing inflammatory bowel diseases (IBD) Biomarker Identification to Remove Contributing Factors and Implement Treatment The initial protocol steps are diagnostic. The main output of these diagnostics will be identification of the biomarker levels and symptoms that reflect abnormalities, and the directions of change required to eliminate these abnormalities. In the present study, hundreds of general and specific biomarkers and symptoms were identified from the core IBD literature. The highest frequency (based on numbers of record appearances) biomarkers and symptoms were extracted, and are listed in Table 1 (highest frequency items first, reading down each column before proceeding to the next column). They are not necessarily consensus biomarkers. They are biomarkers whose values were altered by a treatment or contributing factor, and reported in the core IBD literature.
    [Show full text]